Literature DB >> 24237771

Dantrolene suppresses ventricular ectopy and arrhythmogenicity with acute myocardial infarction in a langendorff-perfused pacing-induced heart failure rabbit model.

Chung-Chuan Chou1,2, Ming-Shien Wen1,2, Hui-Ling Lee3, Po-Cheng Chang1, Hung-Ta Wo1, San-Jou Yeh1,2, Delon Wu1.   

Abstract

INTRODUCTION: Dantrolene prevents arrhythmogenic Ca(2+) release during heart failure (HF). However, direct evidence to support its antiarrhythmic effects in failing hearts with acute myocardial infarction (AMI) is lacking. METHODS AND
RESULTS: HF was induced by right ventricular pacing (312 beats/min, 4 weeks) in 19 rabbits. AMI was induced by coronary artery ligation in rabbits surviving chronic pacing (n = 17). The hearts were quickly excised and Langendorff-perfused for simultaneous membrane potential and intracellular Ca(2+) (Cai ) optical mapping when ventricular fibrillation (VF) occurred or 4 hours after AMI. The VF inducibility was defined as the ability to provoke sustained VF (>2 minutes) by pacing. Dantrolene (10 μM) was administered after baseline studies. Spontaneous VF occurred in 5 rabbits (SVF group). The ventricular premature beat (VPB) burden was significantly higher in the SVF group than the non-SVF group (P < 0.05). Dantrolene suppressed VPB burden (P = 0.03) and prolonged action potential duration (APD; P < 0.05) to reduce VF inducibility (P < 0.05). However, dantrolene shortened immediate postshock APD50 even if VF storm was suppressed.
CONCLUSION: In failing hearts with AMI, VPB burden plays a pivotal role in SVF occurrence. Dantrolene suppresses VPBs and/or prolongs repolarization to inhibit spontaneous VF and reduce VF inducibility.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  calcium; dantrolene; heart failure; myocardial infarction; optical mapping; pharmacology; ventricular fibrillation

Mesh:

Substances:

Year:  2013        PMID: 24237771     DOI: 10.1111/jce.12320

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  6 in total

1.  Essential Role of Calmodulin in RyR Inhibition by Dantrolene.

Authors:  Ye Win Oo; Nieves Gomez-Hurtado; Kafa Walweel; Dirk F van Helden; Mohammad S Imtiaz; Bjorn C Knollmann; Derek R Laver
Journal:  Mol Pharmacol       Date:  2015-04-28       Impact factor: 4.436

Review 2.  Dantrolene, a treatment for Alzheimer disease?

Authors:  Li Liang; Huafeng Wei
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jan-Mar       Impact factor: 2.703

3.  Reduced threshold for store overload-induced Ca2+ release is a common defect of RyR1 mutations associated with malignant hyperthermia and central core disease.

Authors:  Wenqian Chen; Andrea Koop; Yingjie Liu; Wenting Guo; Jinhong Wei; Ruiwu Wang; David H MacLennan; Robert T Dirksen; Sui Rong Wayne Chen
Journal:  Biochem J       Date:  2017-08-07       Impact factor: 3.857

4.  Effects of dantrolene on arrhythmogenicity in isolated regional ischemia-reperfusion rabbit hearts with or without pacing-induced heart failure.

Authors:  Chung-Chuan Chou; Hui-Ling Lee; Po-Cheng Chang; Hung-Ta Wo; Ming-Shien Wen; San-Jou Yeh
Journal:  Biomed Res Int       Date:  2015-02-19       Impact factor: 3.411

5.  Optical Mapping Approaches on Muscleblind-Like Compound Knockout Mice for Understanding Mechanistic Insights Into Ventricular Arrhythmias in Myotonic Dystrophy.

Authors:  Chung-Chuan Chou; Po-Cheng Chang; Yi-Chia Wei; Kuang-Yung Lee
Journal:  J Am Heart Assoc       Date:  2017-04-17       Impact factor: 5.501

6.  Effect of flunarizine on defibrillation outcomes and early refibrillation in a canine model of prolonged ventricular fibrillation.

Authors:  Chaofan Xing; Qi Jin; Ning Zhang; Shaohua Liu; Changjian Lin; Qiong Wu; Qingzhi Luo; Ao Liu; Liqun Wu
Journal:  Exp Physiol       Date:  2019-10-09       Impact factor: 2.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.